Bart Barlogie
University of Arkansas Medical Center · 1,115 works · 75,661 citations · h-index 139
Top works
- Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
- A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
- International uniform response criteria for multiple myeloma
- International Staging System for Multiple Myeloma
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
- Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
- The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
- Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
- Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
- Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
- Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
- Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
- High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
- The molecular classification of multiple myeloma
- Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
- Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
- Primary dexamethasone treatment of multiple myeloma
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
- Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors